TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $129,600.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young acquired 24,000 shares of the company’s stock in a transaction on Monday, January 27th. The stock was purchased at an average cost of $5.40 per share, for a total transaction of $129,600.00. Following the completion of the transaction, the chief financial officer now owns 24,000 shares in the company, valued at approximately $129,600. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

TriSalus Life Sciences Price Performance

TLSI stock opened at $5.11 on Friday. The company has a market cap of $155.82 million, a price-to-earnings ratio of -2.05 and a beta of 0.51. The company has a fifty day moving average price of $4.59 and a 200 day moving average price of $4.75. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.42.

Analyst Ratings Changes

Several research firms recently commented on TLSI. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Canaccord Genuity Group cut their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective for the company. Finally, Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $11.79.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TLSI. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter worth about $66,000. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $92,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences during the third quarter worth approximately $108,000. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $184,000. Finally, Geode Capital Management LLC grew its position in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.